Herantis Pharma – executive interview

Herantis Pharma – executive interview

Herantis Pharma — 5 videos in collection

More on this equity

In this interview, we speak to Antti Vuolanto, CEO of Herantis Pharma, and Henri Huttunen, the company’s CSO. We discuss the latest developments for lead asset HER-096, including the Phase Ib trial readout, the supplementary biomarker programme outcomes and plans for a subsequent Phase II trial. We also cover the company’s latest fundraises as well as key upcoming potential catalysts and milestones for investors to watch out for.

Herantis Pharma is a Finland-based clinical-stage biotechnology company focused on developing disease-modifying therapies to stop or reverse the progression of neurodegenerative diseases.


You may also be interested in these:

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.